Neoadjuvante medikamentöse Therapie beim kolorektalen Karzinom

Neoadjuvante Therapiekonzepte sind bei einigen Tumorerkrankungen des Gastrointestinaltraktes seit Langem Standard. Kürzlich publizierte klinische Studien zeigen, dass die neoadjuvante Therapie auch beim Kolonkarzinom für einige Patienten sinnvoll sein kann. Im Folgenden werden die aktuell präsentierten und laufenden Studien zur medikamentösen neoadjuvanten Therapie beim Kolorektalkarzinom vorgestellt.

Schlüsselwörter

Neoadjuvante Chemotherapie - Kolonkarzinom - Immuntherapie - Studien

• Literatur

• 1 Al-Batran SE, Homann N, Pauligk C. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393: 1948-1957
• 2 van Hagen P, Hulshof MC, van Lanschot JJ. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366 (22) 2074-2084
• 3 Bahadoer RR, Dijkstra EA, van Etten B. et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (01) 29-42
• 4 Conroy T, Bosset JF, Etienne PL. et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (05) 702-715
• 5 Jin J, Tang Y, Hu C. et al. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR). J Clin Oncol 2022; 40 (15) 1681-1692
• 6 Garcia-Aguilar J, Patil S, Gollub MJ. et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. Journal of Clinical Oncology 2022; 40 (23) 2546-2456
• 7 Schrag D, Shi Q, Weiser MR. et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med 2023; 389 (04) 322-334
• 8 Morton D, Seymour M, Magill L. et al. Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial. J Clin Oncol 2023; 41 (08) 1541-1552
• 9 Hu H, Huang M, Li Y. et al. Perioperative chemotherapy with mFOLFOX6 or CAPOX for patients with locally advanced colon cancer (OPTICAL): A multicenter, randomized, phase 3 trial. Journal of Clinical Oncology 2022; 40 (Suppl. 16) 3500
• 10 Kjaer ML, Larsen FO, Hollander NH. et al. Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial. Journal of Clinical Oncology 2023; 41.
• 11 Andre T, Shiu KK, Kim TW. et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med 2020; 383 (23) 2207-2218
• 12 Chalabi M, Fanchi LF, Dijkstra KK. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020; 26 (04) 566-576
• 13 Chalabi M, Verschoor YL, van den Berg J. et al. LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study. Annals of Oncology 2022; 33: S1389
• 14 Cercek A, Lumish M, Sinopoli J. et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 2022; 386 (25) 2363-2376
• 15 Kopetz S, Grothey A, Yaeger R. et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med 2019; 381 (17) 1632-1643